- Home
- XPON vs CVKD Comparison
XPON vs CVKD Comparison
Compare XPON & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- CVKD
- Stock Information
- Founded
- XPON 2016
- CVKD 2022
- Country
- XPON United States
- CVKD United States
- Employees
- XPON N/A
- CVKD N/A
- Industry
- XPON Electronic Components
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- XPON Technology
- CVKD Health Care
- Exchange
- XPON Nasdaq
- CVKD Nasdaq
- Market Cap
- XPON 1.8M
- CVKD 17.1M
- IPO Year
- XPON 2022
- CVKD 2023
- Fundamental
- Price
- XPON $3.27
- CVKD $14.45
- Analyst Decision
- XPON
- CVKD Strong Buy
- Analyst Count
- XPON 0
- CVKD 2
- Target Price
- XPON N/A
- CVKD $52.50
- AVG Volume (30 Days)
- XPON 3.1M
- CVKD 59.6K
- Earning Date
- XPON 11-07-2024
- CVKD 11-08-2024
- Dividend Yield
- XPON N/A
- CVKD N/A
- EPS Growth
- XPON N/A
- CVKD N/A
- EPS
- XPON N/A
- CVKD N/A
- Revenue
- XPON $4,998,801.00
- CVKD N/A
- Revenue This Year
- XPON $0.68
- CVKD N/A
- Revenue Next Year
- XPON $29.04
- CVKD N/A
- P/E Ratio
- XPON N/A
- CVKD N/A
- Revenue Growth
- XPON N/A
- CVKD N/A
- 52 Week Low
- XPON $2.09
- CVKD $5.40
- 52 Week High
- XPON $639.00
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- XPON 37.66
- CVKD 56.80
- Support Level
- XPON $2.70
- CVKD $11.19
- Resistance Level
- XPON $4.29
- CVKD $17.95
- Average True Range (ATR)
- XPON 0.77
- CVKD 1.37
- MACD
- XPON 0.50
- CVKD 0.10
- Stochastic Oscillator
- XPON 33.62
- CVKD 49.64
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles ("RV's") and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.